<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02452801</url>
  </required_header>
  <id_info>
    <org_study_id>ALK5461-215</org_study_id>
    <nct_id>NCT02452801</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Safety of ALKS 5461 in Healthy Subjects and Subjects With Hepatic Impairment and Normal Hepatic Function</brief_title>
  <official_title>A Phase 1 Study of the Pharmacokinetics, Safety, and Tolerability of ALKS 5461 in Subjects With Hepatic Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alkermes, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alkermes, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effect of various degrees of hepatic function on the&#xD;
      pharmacokinetics and safety of ALKS 5461.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve from time 0 to infinity (AUC0-inf) following a single dose of ALKS 5461</measure>
    <time_frame>Up to 168 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve from time 0 to time of last measureable concentration (AUC0-last) following a single dose of ALKS 5461</measure>
    <time_frame>Up to 168 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (CMAX) following a single dose of ALKS 5461</measure>
    <time_frame>Up to 168 hours postdose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum plasma concentration (TMAX)</measure>
    <time_frame>Up to 168 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life (T1/2)</measure>
    <time_frame>Up to 168 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance (CL/F)</measure>
    <time_frame>Up to 168 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution (Vz/F)</measure>
    <time_frame>Up to 168 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AEs)</measure>
    <time_frame>Up to 14 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>ALKS 5461</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sublingual tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALKS 5461</intervention_name>
    <description>Single dose, given orally</description>
    <arm_group_label>ALKS 5461</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For all subjects:&#xD;
&#xD;
          -  Has a body mass index (BMI) of 18.0-35.0 kg/m2 and a total body weight &gt;50 kg&#xD;
&#xD;
          -  Agrees to use an approved method of contraception for the duration of the study&#xD;
&#xD;
          -  Additional criteria may apply&#xD;
&#xD;
        For subjects with hepatic impairment:&#xD;
&#xD;
          -  Has mild, moderate, or severe hepatic impairment&#xD;
&#xD;
          -  Has hepatic dysfunction due to hepatocellular disease&#xD;
&#xD;
          -  Additional criteria may apply&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        For all subjects:&#xD;
&#xD;
          -  Has any past history or current finding of a clinically significant observed&#xD;
             abnormality, psychiatric or medical condition other than hepatic impairment&#xD;
&#xD;
          -  Has a history of gastrointestinal surgery, excluding appendectomy or cholecystectomy&#xD;
&#xD;
          -  Is pregnant, planning to become pregnant, or lactating&#xD;
&#xD;
          -  Has a history of clinically significant allergy or a hypersensitivity to opioids&#xD;
&#xD;
          -  Additional criteria may apply&#xD;
&#xD;
        For subjects with hepatic impairment:&#xD;
&#xD;
          -  Has evidence of hepatocellular carcinoma, acute liver disease, biliary obstruction,&#xD;
             severe ascites, severe portal hypertension, surgical systemic shunts, or other&#xD;
             clinically relevant liver-related disorder or condition&#xD;
&#xD;
          -  Has received a liver transplant&#xD;
&#xD;
          -  Has had esophageal variceal bleeding in the past 2 months&#xD;
&#xD;
          -  Additional criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanjeev Pathak, MD</last_name>
    <role>Study Director</role>
    <affiliation>Alkermes, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alkermes Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>May 21, 2015</study_first_submitted>
  <study_first_submitted_qc>May 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2015</study_first_posted>
  <last_update_submitted>February 3, 2016</last_update_submitted>
  <last_update_submitted_qc>February 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

